Unlock instant, AI-driven research and patent intelligence for your innovation.

Freezing dried mycobatctericsis preparation and its preparing method and use

A technology of Mycobacterium vaccae and preparations, applied in the directions of bacteria, anti-inflammatory agents, antiviral agents, etc., can solve the problems of poor treatment effect and large side effects, etc.

Inactive Publication Date: 2007-08-15
ANHUI ZHIFEI LONGCOM BIOPHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The invention uses the high-pressure airflow shearing technology to prepare the cell-free vaccine with the cell wall of Mycobacterium vaccae as the stimulant and the protein as the inducer, which solves the problem of the side effects of foreign related products, which are injected once every six months and have poor therapeutic effect. the puzzle

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0117] 1. Freeze-dried Mycobacterium vaccae preparation (microcal), which contains Mycobacterium vaccae cells and a protective agent, the ratio of the cells to the protective agent is 10 mg / ml, and the protective agent is 4 times the volume of liquid A and 3 times the volume of the mixture of liquid B, the pH value of the protective agent is 7.2:

[0118] The proportion of 4000ml A solution is as follows:

[0119] Sodium Glutamate or Asparagine 10g

[0120] Sucrose 10g

[0121] Sodium chloride 28.8g

[0122] Potassium dihydrogen phosphate anhydrous 17.4g

[0123] The rest is pure water:

[0124] The proportioning ratio of 3000ml B liquid is:

[0125] Sodium Glutamate or Asparagine 7.5g

[0126] Sucrose 7.5g

[0127] Sodium chloride 21.6g

[0128] Anhydrous disodium hydrogen phosphate 54.9g

[0129] The rest is pure water.

[0130] After mixing liquid A and liquid B, add bacteria.

[0131] The protein content in the thallus is: 0.5 mg of the thallus contains 20-22.5 μg...

example 2

[0147] The formula and preparation method of the freeze-dried Mycobacterium vaccae preparation (microcal) of the present invention are the same as Example 1.

[0148] The following are the results of its clinical research on SARS:

[0149] The present invention selects 63 SARS patients, including 31 males and 33 females, with a maximum age of 74 cases, a minimum age of 14 years, and an average age of 39.75±17.97 years. Observational cases received a deep injection of 1 freeze-dried Mycobacterium vaccae preparation (microcart) per week for a total of 3-5 weeks, and some patients also used hormones (methylprednisolone 160-500mg / day). The clinical trials were completed by the 309 Hospital of the Chinese People's Liberation Army. Among them, severe patients (within 48 hours, chest radiographs showed that the lesion progressed by more than 50%, the lesion occupied 5-6 lung fields and had persistent high fever, and the respiratory rate was more than 30 times / min in a calm state , o...

example 3

[0152] The formula and preparation method of the freeze-dried Mycobacterium vaccae preparation (microcal) of the present invention are the same as Example 1.

[0153] For 40 cases of cancerous pleural effusion treated with intrathoracic infusion immunotherapy, the complete effective rate was 60% (12 / 20), and the effective rate was 90% (18 / 20), both of which were significantly higher than those of the control group (P less than 0.05).

[0154] The use of microcards in the treatment of prostate cancer, melanoma, non-small cell lung cancer and mesothelioma patients has also shown good results. The quality of life of patients is generally improved, the pain is relieved, and the survival time is significantly prolonged.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
oxygen indexaaaaaaaaaa
Login to View More

Abstract

A freeze dried cow mycobacterium medicine (Weika) for treating tumors, hepatitis B, AIDS, dermatopathy, dermatitis, cold, rheumatoid arthritis and asthma is prepared from cow mycobacteria and protecting agent containing sodium glutamate or aspartocin, cane sugar, sodium (or potassium) chloride, anhydrous potassium bihydrogen phosphate, anhydrous bihydrogen phosphate and water. Its preparing process is also disclosed.

Description

technical field [0001] The invention relates to a biological vaccine preparation, in particular to a Mycobacterium vaccae vaccine preparation with immune regulation function. Background technique [0002] Mycobacterium vaccae was isolated from bovine mammary glands by Bonicke et al. in 1964. Tsukamura confirmed in 1968 that the bacterium is a fast-growing mycobacterium, widely distributed in nature, and found in grasslands, pastures, and ponds. The bacteria were short bacillus plump. 1.0-4.0 microns long, slightly curved, rounded at both ends or occasionally thick. Sparsely branched but occasional phenotype cells can be observed on egg medium for 2 to 3 days and usually produce smooth, moist, luminous, creamy gardener-type colonies with dark yellow to orange pigments. Growth in the dark for 1 to 2 days is non-pigmentation, but after a short exposure, it becomes a yellow pigment. The growth temperature of the bacteria is 22-40°C. When cultured at 17°C and 42°C, the growth i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/74A61P35/00A61P31/12A61P31/18A61P31/00A61P29/00A61P17/00A61P11/06
Inventor 李炜陶立峰
Owner ANHUI ZHIFEI LONGCOM BIOPHARM CO LTD